Literature DB >> 1312720

Relaxin binding in the rat heart atrium.

P L Osheroff1, M J Cronin, J A Lofgren.   

Abstract

Relaxin is a member of the insulin family of polypeptides that is best known as a reproductive hormone. In an effort to elucidate the mechanism of action of relaxin we previously localized the specific binding sites of a 32P-labeled relaxin in the rat uterus and brain. These studies suggested that, in addition to its classical role in pregnancy, relaxin might have other physiological functions. In the present paper we describe the specific and high-affinity binding of relaxin to the cardiac atrium of both male and female rats. The relaxin binding could not be displaced by peptides belonging to the same family [insulin, insulin-like growth factor I (IGF-I)] or by peptides that were identified in the atrium or were known to have cardiovascular functions (atrial natriuretic peptide, angiotensin II). The dissociation constant for relaxin in the atrium was estimated to be 1.4 nM, which was similar to that found in the uterus (1.3 nM) and the brain (1.4 nM). In view of the close association of relaxin with reproduction, an experiment was also performed to compare the relaxin binding in the uterus and heart after gonadectomy and sex steroid treatment. It was found that the relaxin binding in the rat uterus was diminished by 53% overall following ovariectomy but was restored to 90% of normal levels when treated with estrogen (but not with testosterone). In contrast, the relaxin binding in the rat heart was not affected by castration or sex steroid treatment. We conclude that specific and high-affinity relaxin receptors exist in the atrium of both the male and female rat heart and that these are regulated differently than the relaxin receptors in the uterus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312720      PMCID: PMC48662          DOI: 10.1073/pnas.89.6.2384

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Bioassay of relaxin using a reference standard: a simple and reliable method utilizing direct measurement of interpubic ligament formation in mice.

Authors:  B G STEINETZ; V L BEACH; R L KROC; N R STASILLI; R E NUSSBAUM; P J NEMITH; R K DUN
Journal:  Endocrinology       Date:  1960-07       Impact factor: 4.736

2.  Relaxin in the peri-implantation period.

Authors:  D R Stewart; A C Celniker; C A Taylor; J R Cragun; J W Overstreet; B L Lasley
Journal:  J Clin Endocrinol Metab       Date:  1990-06       Impact factor: 5.958

3.  Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts.

Authors:  E N Unemori; E P Amento
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

4.  Erythropoietin receptor and interleukin-2 receptor beta chain: a new receptor family.

Authors:  A D D'Andrea; G D Fasman; H F Lodish
Journal:  Cell       Date:  1989-09-22       Impact factor: 41.582

5.  Delineation of atypical insulin receptors from classical insulin and type I insulin-like growth factor receptors in human placenta.

Authors:  H A Jonas; A J Cox; L C Harrison
Journal:  Biochem J       Date:  1989-01-01       Impact factor: 3.857

6.  A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain.

Authors:  J F Bazan
Journal:  Biochem Biophys Res Commun       Date:  1989-10-31       Impact factor: 3.575

Review 7.  Relaxin in the male.

Authors:  G Weiss
Journal:  Biol Reprod       Date:  1989-02       Impact factor: 4.285

8.  Regulation of epidermal growth factor and insulin-like growth factor I receptors by estradiol and progesterone in normal and neoplastic endometrial cell cultures.

Authors:  R K Reynolds; F Talavera; J A Roberts; M P Hopkins; K M Menon
Journal:  Gynecol Oncol       Date:  1990-09       Impact factor: 5.482

9.  The steroid-dependent regulatory element in the ovalbumin gene does not function as a typical steroid response element.

Authors:  L A Schweers; D E Frank; N L Weigel; M M Sanders
Journal:  J Biol Chem       Date:  1990-05-05       Impact factor: 5.157

10.  Relaxin affects the release of oxytocin and vasopressin from the neurohypophysis.

Authors:  G Dayanithi; M Cazalis; J J Nordmann
Journal:  Nature       Date:  1987 Feb 26-Mar 4       Impact factor: 49.962

View more
  14 in total

Review 1.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 2.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

Review 3.  Relaxin and fibrosis: Emerging targets, challenges, and future directions.

Authors:  Anthony J Kanai; Elisa M Konieczko; Robert G Bennett; Chrishan S Samuel; Simon G Royce
Journal:  Mol Cell Endocrinol       Date:  2019-02-14       Impact factor: 4.102

4.  Relaxin enhances the coronary outflow in perfused guinea-pig heart: correlation with histamine and nitric oxide.

Authors:  M G Di Bello; F Gambassi; L Mugnai; M Lupini; T Bani Sacchi; M Bigazzi; P F Mannaioni; E Masini
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

5.  Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: characterization and effects of oestrogen treatment.

Authors:  Y Y Tan; J D Wade; G W Tregear; R J Summers
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 6.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

7.  Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin.

Authors:  Andrew R Kompa; Chrishan S Samuel; Roger J Summers
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

8.  Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts.

Authors:  Ashish Parikh; Divyang Patel; Charles F McTiernan; Wenyu Xiang; Jamie Haney; Lei Yang; Bo Lin; Aaron D Kaplan; Glenna C L Bett; Randall L Rasmusson; Sanjeev G Shroff; David Schwartzman; Guy Salama
Journal:  Circ Res       Date:  2013-06-07       Impact factor: 17.367

Review 9.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

10.  Relaxin-induced increased coronary flow through stimulation of nitric oxide production.

Authors:  T Bani-Sacchi; M Bigazzi; D Bani; P F Mannaioni; E Masini
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.